Jazz Pharmaceuticals: Muscle Spasticity trials

The registry lists 11 Muscle Spasticity studies with Jazz Pharmaceuticals as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 3 10Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisTerminatedNCT04984278Phase 3Results posted
• Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisCompletedNCT04657666Phase 3Results posted
• Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple SclerosisTerminatedNCT04203498Phase 3Results posted
• A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis PatientsCompletedNCT01964547Phase 4Results posted
• A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple SclerosisCompletedNCT01610687Phase 3Results posted
• A Study of the Long-term Safety of Sativex UseCompletedNCT01606137Phase 3Results posted
• A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.CompletedNCT00711646Phase 3Results posted
• Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple SclerosisCompletedNCT00702468Phase 3Results posted
• A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)CompletedNCT00681538Phase 3Results posted
• A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 YearsCompletedNCT01898520Phase 3
• Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.WithdrawnNCT01868048Phase 3